Bayer Launches Co.Lab Berlin, MyoPax Joins as First Resident

Bayer has officially launched Bayer Co.Lab Berlin, a new life science incubator located at the company’s Pharmaceuticals Division Global Headquarters Campus in Berlin. The facility is designed to support start-ups with advanced laboratory spaces, collaborative environments, and tailored resources to accelerate biotech innovation. MyoPax GmbH, a Berlin-based start-up specialising in muscle regeneration therapies, will be the first resident. A spin-off from Charité Universitätsmedizin and the Max-Delbrück-Centre, MyoPax will utilise the incubator to advance its muscle stem cell platform aimed at developing treatments for muscle-related conditions.

Bayer Co.Lab Berlin is part of Bayer’s global network of life science incubators, which also includes facilities in Cambridge (USA), Kobe (Japan), and Shanghai (China). The initiative is a key component of Bayer’s external innovation strategy, aimed at fostering collaboration within the biotechnology ecosystem. According to Juergen Eckhardt, MD, Head of Business Development & Licensing at Bayer Pharmaceuticals, the incubator will play a critical role in positioning Berlin as a leading hub for biotechnology. It will also complement the future Berlin Centre for Gene and Cell Therapies, slated to open in 2028, providing a pathway for growth and innovation in gene and cell therapies.

Kai Wegner, Governing Mayor of Berlin, emphasised the importance of the new incubator in strengthening Berlin’s healthcare sector. He noted that Bayer Co.Lab Berlin will bridge the gap between science and industry, accelerating the development of innovative therapies. Start-ups joining the incubator will benefit from mentorship, access to Bayer’s global expertise in research and development, and connections to ecosystem partners, all designed to help them advance their technologies from concept to clinic. This launch further solidifies Bayer’s commitment to fostering biotech innovation and supporting the next generation of healthcare solutions.